0.529
0.00 (-0.04%)
| Previous Close | 0.529 |
| Open | 0.529 |
| Volume | 455,804 |
| Avg. Volume (3M) | 2,776,783 |
| Market Cap | 51,869,092 |
| Price / Sales | 247.76 |
| Price / Book | 0.830 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Diluted EPS (TTM) | -0.800 |
| Total Debt/Equity (MRQ) | 17.35% |
| Current Ratio (MRQ) | 7.80 |
| Operating Cash Flow (TTM) | -62.16 M |
| Levered Free Cash Flow (TTM) | -37.33 M |
| Return on Assets (TTM) | -39.82% |
| Return on Equity (TTM) | -79.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | aTyr Pharma, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | -1.00 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.23% |
| % Held by Institutions | 69.63% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |